Merck

Merck

Yahoo Finance • yesterday

FDA Approves Merck's KEYTRUDA + Padcev Regimens For Muscle-Invasive Bladder Cancer

(RTTNews) - Merck & Co Inc. (MRK) announced that the U.S. Food and Drug Administration approved KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), the company's anti-PD-1 therapies, each in combinat... Full story

Yahoo Finance • 2 days ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

First and only PD-1 inhibitor plus antibody-drug conjugate regimens approved for patients with MIBC regardless of cisplatin eligibility Approvals based on Phase 3 KEYNOTE-B15 trial, combined with previous approvals based on Phase 3 KEYNOT... Full story

Yahoo Finance • 2 days ago

Pfizer wins FDA label expansion for Padcev plus Merck’s Keytruda in bladder cancer

[US Food and Drug Administration (FDA)] * The U.S. Food and Drug Administration on Friday approved a label expansion for a drug regimen combining Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) and Astellas’ (ALPMF [https://seekingal... Full story

Yahoo Finance • 3 days ago

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

VanEck Pharmaceutical ETF (NASDAQ:PPH) offers concentrated exposure to global drugmakers, while Vanguard Health Care ETF (NYSEMKT:VHT) provides a much broader, lower-cost entry point into the diverse healthcare landscape. Both funds targe... Full story

Yahoo Finance • 3 days ago

Will New KEYTRUDA Breast and Bladder Cancer Approvals Redefine Merck’s (MRK) Post-Exclusivity Narrative?

In late June 2026, Merck reported multiple oncology milestones, including U.S. FDA approval of KEYTRUDA and KEYTRUDA QLEX plus Trodelvy for first-line PD-L1–positive advanced triple-negative breast cancer and EU approval of KEYTRUDA plus P... Full story

Yahoo Finance • 4 days ago

Former Merck and NASA Veterans Join SpaceMD as Space Pharma Momentum Builds

By Karen Roman Redwire Corporation (NYSE: RDW) said it designated Paul Reichert and Niki Werkheiser to serve at strategic advisory roles at Space Microgravity Development (SpaceMD), Redwire's venture company focused on the microgravity en... Full story

Yahoo Finance • 4 days ago

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

The State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH) offers broader exposure and lower historical volatility than the VanEck Biotech ETF (NASDAQ:BBH), which relies on a smaller group of biotechnology leaders. While both funds offer... Full story

Yahoo Finance • 4 days ago

Former Merck and NASA Leaders Bring Strategic Expertise to SpaceMD Amid Rising Demand for its In-Space Pharmaceutical Development Capabilities

JACKSONVILLE, Fla., July 08, 2026--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, announced today it has appointed pioneering industry leaders Paul Reichert, former Principa... Full story

Yahoo Finance • 5 days ago

The Dividend ETF Quietly Outperforming the S&P 500

The iShares Core High Dividend ETF (NYSEMKT: HDV) isn't as large or as popular as other dividend ETFs. As a result, many investors have likely missed that the fund is outperforming the S&P 500 this year. While that broad market index was u... Full story

Yahoo Finance • 6 days ago

Stock Market Today: Dow Up, AI Stock Tests Entry; TeraWulf Cedes Key Level Despite Anthropic Deal (Live Coverage)

The Dow Jones index fell but other indexes rallied as President Trump made bullish comments. Microsoft fell on the stock market today while Micron rose. Continue Reading... Full story

Yahoo Finance • 6 days ago

This Low-Cost ETF Is Trouncing the S&P 500 in 2026 and Could Outperform for Another Decade, According to Analysts

Key Points ETFs can be a great way to tilt your portfolio toward a certain market segment or industry. This Schwab ETF offers a better alternative than more traditional funds in its category. This factor is poised to outperform over the n... Full story

Yahoo Finance • 7 days ago

Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year

Quick Read SCHD has delivered 227% over 10 years and screens every holding for 10 consecutive years of dividend payments before allowing entry. KO raised its dividend for the 63rd straight year, while VZ's 6.5% yield is backed by free cas... Full story

Yahoo Finance • 7 days ago

IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?

The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers lower fees and a higher dividend yield, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) spreads its holdings more evenly across the sector's biggest players. Investors seeking... Full story

Yahoo Finance • 7 days ago

Merck (MRK) Wins New KEYTRUDA Approvals As Tulisokibart Clears A Phase 3 Test

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antib... Full story

Yahoo Finance • 8 days ago

Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?

The VanEck Pharmaceutical ETF (NASDAQ:PPH) offers a more cost-efficient entry point and higher income potential, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) has recently demonstrated stronger price appreciation for investors seekin... Full story

Yahoo Finance • 9 days ago

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

As the biotechnology landscape shifts toward personalized medicine and advanced computing, investors are weighing established leaders against emerging tech-driven disruptors. Moderna (NASDAQ:MRNA) and Recursion Pharmaceuticals (NASDAQ:RXRX... Full story

Yahoo Finance • 9 days ago

If You Put $10,000 in This Dividend ETF 15 Years Ago, Here's How Much You'd Have Today (Hint: It's a Lot)

Key Points The Schwab U.S Dividend Equity ETF has delivered a CAGR of 13.3% since 2011. Dividends make up roughly 38% of the ETF's total returns.10 stocks we like better than Schwab U.S. Dividend Equity ETF › Do you view dividend investi... Full story

Yahoo Finance • 9 days ago

[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Antidiabetic Drugs Market size & share revenue was valued at approximately USD 103.21... Full story

Yahoo Finance • 10 days ago

Merck Stock, JPMorgan And Two Others Hit New Highs

Merck stock is in a buy zone after hitting a new high. Fellow Dow stock JPMorgan Chase and Amphenol are both trading around entry points. Continue Reading... Full story

Yahoo Finance • 10 days ago

Sector Update: Healthcare Stocks Gain Thursday Afternoon

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 2% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story